Biology
↗What is myostatin? MSTN, GDF-8, and muscle regulation
Understand the gene and protein at the center of myostatin research, and the limits of the “muscle brake” analogy.
Myostatin research & clinical evidence
Explore study notes, foundational biology, and methods for interpreting myostatin research. Filter by subject or search a trial name.
Biology
↗Myostatin signaling: ligand, receptor, and intervention points
A conceptual guide to where myostatin-targeting approaches act and why pathway position does not predict clinical benefit by itself.
SMA research
↗SAPPHIRE apitegromab trial: results and interpretation
Read the SMA population, motor-function outcome, pooled effect estimate, and later FDA-label context of SAPPHIRE.
Body composition
↗Bimagrumab 2021 trial: fat mass, lean mass, and body weight
Read the 48-week phase 2 results while keeping fat loss, total weight loss, and lean-tissue change separate.
Body composition
↗BELIEVE trial: bimagrumab and semaglutide in obesity
A guide to the 2026 phase 2 publication, selected weight-change results, combination-treatment context, and limitations.
Emerging findings
↗COURAGE trevogrumab results: DXA and MRI are different
Interpret the October 2026 sponsor report without confusing whole-body lean-mass change with thigh-muscle preservation.
Muscular dystrophy
↗MYO-029 trial: why muscle size and function must be separated
An earlier randomized myostatin-antibody study illustrates the limits of exploratory results and broad effectiveness claims.
Research methods
↗How to read a myostatin clinical trial
A practical framework for interpreting populations, endpoints, confidence intervals, study arms, and evidence limits.
Biology
↗MSTN gene mutations and myostatin-related muscle hypertrophy
What a rare genetic condition teaches about myostatin, and why genetic observations cannot substitute for drug-trial evidence.
No matching articles. Try another term or choose “All topics.”